NCT06001788 2025-12-03Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT05963217 2025-07-02Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLUniversity Health Network, TorontoPhase 1 Recruiting19 enrolled